Advancing Precision Medicine Through Pathology and AI-Powered CDx with Indica Labs
5 May 2026 | Learn about Indica Labs’ ability to deliver AI-driven CDx
Advancing Precision Medicine Through Pathology and AI-Powered CDx with Indica Labs Read More »
5 May 2026 | Learn about Indica Labs’ ability to deliver AI-driven CDx
Advancing Precision Medicine Through Pathology and AI-Powered CDx with Indica Labs Read More »
Learn more about the automated quality control and benefits of SlideQC BF.
SlideQC BF Brochure Read More »
Learn more about the automated workflow and benefits of HALO Macrodissection Solutions
HALO Macrodissection Solutions Brochure Read More »
AI-powered digital pathology is redefining modern cancer care by extending clinical-grade insights beyond the microscope and enabling standardized, pixel-level analysis to support scalable cancer diagnostics anytime, anywhere.
Albuquerque, NM, March 3, 2026 – Indica Labs, the global leader in AI-powered digital pathology software and services, today announces surpassing the 3,000th installation of HALO software worldwide.
We are proud to mark a significant milestone: HALO AP® earned the highest overall customer rating in the 2026 KLAS Global Software report for digital pathology. Because KLAS distinction is driven entirely by direct customer feedback, this recognition reflects the real-world performance, reliability, and impact of our platform in daily pathology practice.
KLAS Recognition as a Catalyst for What Comes Next Read More »
16 April 2026 | Learn about the exciting new features in the 2.5 versions of HALO AP®!
HALO AP 2.5 Sneak Peek Webinar Read More »
Albuquerque, NM, February 12, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced recognition by KLAS for top customer-rated performance in the European digital pathology market.
HALO AP® is Now Rated in Best in KLAS®: Earning ‘A’ Grades in All Categories Read More »
Albuquerque, NM, February 10, 2025 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI . The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026.
As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.
Looking Back: Reviewing 2025 at Indica Labs Read More »